TET2 and melanoma: To elucidate how α-KG enhances the efficacy of anti-PD1 immunotherapy in melanoma, we conducted RNA sequencing of tumors treated with α-KG, anti-PD1 or α-KG + anti-PD1 and found that IFNG-STAT1/3-CD274 signaling and α-KG-dependent TET2/3 were significantly altered in the α-KG + anti-PD1 mAb group.